Skip to content

Aripiprazle in ADHD and ODD

The effect of betahistine on hyperactivity disorder in children

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160530028182N6
Enrollment
76
Registered
2019-05-15
Start date
2018-05-22
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit/hyperactivity disorder. Attention deficit/hyperactivity disorder

Interventions

Intervention 1: Intervention group: the research consisted of 76 participants who were randomly assigned to receive intervention and control group. Ritalin 10 mg for the first week of the week (one ha

Sponsors

Sanandaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 18 Years

Inclusion criteria

Inclusion criteria: Age between 8-18 years Diagnosis of ADHD and ODD based on DSM5 without effective medication Taking on mental status at least 2 weeks before the study

Exclusion criteria

Exclusion criteria: Intelectual disability based on clinical suspicious Presence of uncontroled siezure Drug side effects and hypersensivity Recieving of any other drugs History of psychological disorder except for ADHD and ODD Presence of medical diseases such as cardiac diseases

Design outcomes

Primary

MeasureTime frame
Improvment in Attention-deficit symptoms. Timepoint: Baselin, second, fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.

Secondary

MeasureTime frame
Severity of ADHD symptoms. Timepoint: Baselin, second, fourth and eighth weeks after intervention. Method of measurement: ADHD Rating scale and CGI.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoleiman Mohammadzadeh

Sanandaj University of Medical Sciences

dr.mohammadzadeh86@muk.ir+98 87 3366 4653

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026